Loading...
•
Dec 31, 2023
Amneal Q4 2023 Earnings Report
Amneal's Q4 2023 performance was marked by a net revenue of $617 million, alongside a GAAP net loss of $99 million, and an adjusted diluted EPS of $0.14.
Key Takeaways
Amneal reported a 1% increase in net revenue to $617 million for Q4 2023. However, the company experienced a GAAP net loss of $99 million, and an adjusted diluted EPS of $0.14.
Net revenue increased by 1% to $617 million compared to Q4 2022.
GAAP net loss was $99 million, compared to a net loss of $4 million in Q4 2022.
Adjusted EBITDA decreased by 8% to $142 million compared to Q4 2022.
Adjusted diluted EPS was $0.14, a decrease of 39% from Q4 2022.
Amneal
Amneal
Amneal Revenue by Segment
Revenue by Segment
Affordable Medicines Revenue
CapyFin.comSpecialty Revenue
CapyFin.comAvKARE Revenue
CapyFin.com Forward Guidance
Amneal provides 2024 financial guidance of $2.55 to $2.65 billion in net revenue and $580 to $620 million in Adjusted EBITDA.
Revenue & Expenses
Visualization of income flow from segment revenue to net income